COVID-19
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
Earlier this week, Sanofi’s chief executive officer Paul Hudson indicated that the U.S. would have first access to its COVID-19 vaccine because of the significant financial support it is receiving from the U.S. government.
Following a study that raises concerns about the accuracy of Abbott’s rapid COVID-19 test for detecting the virus, the U.S. Food and Drug Administration (FDA) announced it will investigate the claims found in a New York University-related study as the company updates its guidance on the ID NOW test.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Researchers at a New York hospital compared Abbott’s 15-minute Abbott ID NOW test to another COVID-19 diagnostics device and found that the Abbott system missed 48% of positive cases the other device detected.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Following the announcement that Slaoui was tapped to helm Operation Warp Speed, Jim Greenwood, president and CEO of BIO, hailed that decision.
Although many cyber criminals have pledged not to attack healthcare providers during the COVID-19 pandemic, one expert tells CNBC that this may not extend to pharmaceutical companies.
The designation will expedite regulatory review of the medication should it prove to be safe and effective.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.
PRESS RELEASES